Safety and efficacy of multi-kinase inhibitor plus endostar treatment in patients with metastatic renal cell carcinoma and pleural effusion

摘要

Objective The aim of this study was to evaluate the safety and efficacy of multi-kinase inhibitor plus endostar treatment in patients with metastatic renal cell carcinoma(mRCC)and pleural effusion.Methods A total of 10 patients with mRCC(8 clear-cell RCCs,1 papillary RCC,1 chromophobe RCC)with pleural effusion from January 2014 to October 2015 were recruited.Four patients received sorafenib(400 mg,twice daily),while six received sunitinib(50 mg,once daily;2 weeks on and 1 week off).All patients received multi-kinase inhibitor plus pleural cavity perfusion of endostar(15 mg on days 1–4 for 1 or 2 weeks).Results The response rate of pleural effusion was 70%.Adverse reactions were limited and mild.Conclusion The regimen of multi-kinase inhibitor plus pleural cavity perfusion of endostar was both effective and safe for the treatment of patients with mRCC with pleural effusion,and may control local symptoms.